



聯康生物科技集團有限公司

Uni-Bio Science Group Limited

To: Business Editor [For immediate release]

PROPOSED ACQUISITION OF THE ENTIRE ISSUED SHARE CAPITAL OF ZETHANEL

**ACQUISITION OF A FACTORY IN SHENZHEN WITH CLASS I PRESCRIPTION NEW DRUG CERTIFICATE AND
GMP CERTIFICATE**

FURTHER CONSOLIDATE THE MARKET LEADING POSITION IN THE BIO-SCIENCE INDUSTRY

(3 July 2007, Hong Kong) Uni-Bio Science Group Limited (“Uni-Bio” or the “Group”, SEHK: 690), today announced that on 2 July 2007, Lelion, a wholly-owned subsidiary of the Group, entered into the exclusivity agreement with two independent third parties (“Potential Sellers”) in respect of the possible acquisition of the entire issued share capital of Zethanel Properties Limited (“Zethanel”). Trading in the securities of the Group has been resumed at 2:30 pm on 3 July 2007 at Hong Kong Stock Exchange.

Zethanel is an investment holding company incorporated in the British Virgin Islands and its entire issued share capital is beneficially owned by the Potential Sellers. The principal asset of Zethanel is the holding of the entire registered capital of Shenzhen Watsin Genetech Ltd. (“Shenzhen Watsin”).

Amount of Consideration

At this stage, the parties to the exclusivity agreement have not yet formulated definitive terms of the Possible Acquisition, so the estimated amount of the consideration has not been determined yet. Nevertheless, the Potential Sellers have indicated their preference to receive a combination of cash and equity or equity-linked consideration from the Group as consideration for the possible acquisition. The Group will consider such proposal but no decision has yet been made by the Group regarding the means or the exact source of funding for the proposed acquisition.

Earnest Money

In consideration of the Potential Seller agreeing to enter into the exclusivity agreement, a refundable sum of HK\$1,000,000 as earnest money will be paid by Lelion to the Potential Sellers within 5 days from the date of signing of the exclusivity agreement. If no definitive agreement relating to the possible acquisition is concluded with the Potential Sellers within 90 days from the date of the exclusivity agreement (or such longer period as the parties may agree) or if Lelion indicates to the Potential Sellers that it no longer wishes to proceed with the negotiation under the exclusivity agreement, the earnest money will be refunded to Lelion without interest. If a definitive agreement relating to the possible acquisition is entered into, the earnest money will be treated as deposit for the possible acquisition and be released, held or returned in accordance with the terms of the definitive agreement.

Mr. Tong Kit Shing, Chairman of Uni-Bio said, “Through signing this exclusivity agreement and identifying other investment opportunities with potential, the Group has further implemented its prudent expansion plan for its bio-science related business. Once the possible acquisition is materialized, a platform will be created for the Group to further develop its bio-science related business, consolidate further its market position and maintain overall competitiveness in the bio-science related industry in the PRC in the long run.”

Mr. Tong added, “Looking forward, we will go on to reinforce our R&D efforts and expand the Group’s capacity. Leveraging on our vertically integrated production process, we are fully confident that the Group will enhance its overall competitiveness, enlarge its economy of scale, and maximize our shareholders’ return.”

- End -

About Shenzhen Watsin Genetech Ltd.

Shenzhen Watsin is a wholly-foreign owned enterprise established in the PRC and currently has a registered paid-up capital of RMB80,000,000. It is principally engaged in technology development of genetic engineering, bio-pharmaceuticals, manufacturing and selling of recombinant human epidermal growth factor in liquid preparations. Shenzhen Watsin has obtained a new drug and GMP certificate for recombinant human epidermal growth factor derivative for external use (“EGF”)(which is a Class I prescription new drug) issued by the Ministry of Health of the PRC and GMP certificate for EGF (in the form of eye drops) issued by the State Food and Drug Administration of the PRC.

About Uni-Bio Science Group Limited (SEHK: 0690)

Uni-Bio Science Group Limited is dedicated to the discovery, development and commercialization of biopharmaceuticals through recombinant DNA and other technologies. The Group has commenced research and development into a diversified portfolio of pharmaceutical products at various stages of development, including treatments for type 2 diabetes, osteoporosis, cancer, infectious disease, inflammatory conditions and immune system disorders.

Released by the **Elite Communications Group Limited** for and on behalf of **Uni-Bio Science Group Limited**. For further information, please contact:

Investor Relations

Ms. Cindy Xin

Tel.: 3183 0226

Fax: 2155 9165

Media Relations

Ms. Alice Li / Ms. Gigi Wong

Tel.: 3183 0232 / 3183 0235

Fax: 2583 9138